Table 1.
Underlying medical conditions for which both PCV13 and PPSV23 are currently recommended by ACIP for individuals ≥6 y of age.14-16
| Risk group | Underlying medical conditions |
|---|---|
| Immunocompetent | • Cerebrospinal fluid leak |
| • Cochlear implant | |
| Functional or anatomic asplenia | • Sickle cell disease/otherhemaglobinopathy |
| • Congenital or acquired asplenia | |
| Immunocompromised | • Congenital or acquired immunodeficiency |
| • HIV infection | |
| • Chronic renal failure | |
| • Nephrotic syndrome | |
| • Leukemia | |
| • Lymphoma | |
| • Hodgkin disease | |
| • Generalized malignancy | |
| • Iatrogenic immunosuppression | |
| • Solid organ transplant | |
| • Multiple myeloma |
ACIP = Advisory Committee on Immunization Practices; PCV13 = 13-valent pneumococcal conjugate vaccine; PPSV23 = 23-valent pneumococcal polysaccharide vaccine.